CD8A and glioblastoma: To prove this conjecture, a randomized pilot trial in patients with newly diagnosed GBM was conducted to demonstrate that HCMV pp65 RNA-loaded DC vaccination experienced enhanced tumor-specific CD8+ T cell polyfunctionality and significantly increased overall survival [63].